CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Biomarker
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
    Technologies and Software
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

The New Era of Representative Science: Advancing Diversity in Clinical Research

The pharmaceutical industry is moving toward precision health by prioritizing diversity in clinical trials. Through proactive recruitment strategies, deeper community engagement, technology enabled outreach, and culturally competent practices, research organizations are working to improve representa 

By

Life Sciences Review | Tuesday, February 24, 2026

The pharmaceutical industry is undergoing a decisive shift from the era of generalized medicine to the age of precision health. As the field evolves, the meaning of clinical excellence is being redefined. It is no longer sufficient to show that a therapeutic asset is safe and effective in broad populations. The new standard demands clarity about for whom it is safe, for whom it is effective, and how outcomes vary across diverse patient groups.


In this context, the pursuit of diversity in clinical trials has evolved from a matter of corporate social responsibility into a fundamental pillar of scientific integrity. The industry is currently witnessing a massive operational shift, moving away from passive enrollment techniques toward proactive, structurally embedded inclusive recruitment strategies. By aligning clinical data with the actual demographics of the patient populations they serve, pharmaceutical companies and Contract Research Organizations (CROs) are unlocking deeper insights into pharmacokinetics, genetic variability, and treatment responses.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.


Cultivating Deep-Rooted Community Ecosystems


The most notable strategic shift in recent years has been the transition from transactional recruitment—where engagement begins and ends with a single study—to the development of long-term community ecosystems. Industry leaders increasingly recognize that sustained diversity in clinical research requires a relationship-driven model that begins well before any protocol is drafted. This shift underscores the value of building trust, familiarity, and shared purpose with communities over time, rather than relying on isolated outreach efforts tied to individual trials.


A central component of this evolution is the emphasis on co-creation and early engagement. Instead of presenting communities with a fully developed protocol, progressive sponsors are involving patient advocacy groups and community leaders during the design phase. This includes consulting diverse patient panels to review inclusion and exclusion criteria and ensuring that study parameters do not unintentionally exclude specific demographic groups due to lifestyle, cultural, or socioeconomic factors. By integrating the patient perspective early, organizations are creating studies that are more accessible and inherently aligned with the needs of the populations they aim to serve.


Another significant operational advancement is the formal introduction of the Community Liaison—or Cultural Broker—role. These individuals extend far beyond traditional recruitment functions. Embedded within demographic communities, they serve as trusted intermediaries, translating complex clinical concepts into culturally meaningful, easy-to-understand language. This approach draws on principles of health literacy to support genuine informed consent, enabling potential participants to make confident, autonomous decisions about trial involvement.


The expansion of grassroots partnerships further reinforces this relationship-centered approach. Clinical research engagement is increasingly moving beyond academic medical centers into community-based settings such as faith organizations, local pharmacies, and neighborhood health centers. Establishing a presence in the environments where diverse populations live and receive care strengthens the connection between primary healthcare and clinical research. This community-level accessibility fosters continuity, reduces participation barriers, and builds a more inclusive research ecosystem.


Technology as an Equalizer: The Decentralization Revolution


Human connection continues to serve as the foundation of clinical research, yet technology now provides the infrastructure required to scale inclusivity. The rapid adoption of Decentralized Clinical Trials (DCTs) and hybrid models has emerged as a powerful equalizer, gradually eliminating the geographical and logistical barriers that have historically restricted participation.


The integration of remote monitoring and telehealth platforms enables participants to consult with investigators from their homes, significantly reducing travel requirements and minimizing disruptions to work and personal responsibilities. This patient-centric logistics model enhances accessibility for individuals in rural communities, those with hourly wage constraints, and caregivers who face challenges in adhering to traditional site-visit schedules. By effectively bringing the trial to the participant, the industry broadens its recruitment landscape from a limited local radius to an entire region or nation.


In parallel, the use of medical-grade wearables and digital endpoints allows for continuous, real-time data collection without the need for frequent in-person clinical engagements. A Bring Your Own Device (BYOD) model—supported by provisioned devices when necessary—further democratizes access. Participation is no longer determined by proximity to major medical centers but by a candidate’s clinical suitability for the study.


Behind the scenes, data-driven site selection is reshaping operational strategies. Advanced analytics and Artificial Intelligence (AI) now enable sponsors to move beyond historical site performance, which often perpetuates homogenous patient pools. By leveraging real-world data and heat-mapping technologies, organizations can identify high-prevalence areas across diverse demographic groups and establish investigative sites within underrepresented regions. This approach ensures that infrastructure is intentionally placed where patient needs are most concentrated, strengthening the inclusivity and representativeness of clinical trials.


Structural and Operational Transformation


Pharmaceutical companies increasingly recognize that achieving diverse patient participation requires a trial infrastructure that reflects the same diversity. This extends beyond patient outreach to include the composition of principal investigators and site staff, whose representation plays a critical role in shaping participant trust and engagement.


A growing industry-wide initiative is focused on broadening the investigator pipeline by recruiting and training principal investigators and site personnel from underrepresented backgrounds. Evidence shows a clear link between staff diversity and more inclusive patient enrollment. When individuals see healthcare professionals who share or understand their cultural experiences, comfort and confidence increase, ultimately improving retention. In response, sponsors are allocating resources to mentorship programs and infrastructure support that help community-based physicians develop the skills needed to participate as clinical researchers.


In parallel, operational frameworks now emphasize cultural competence as a core component of site readiness. Training on cultural awareness and implicit bias has become mandatory for site teams and recruitment partners to ensure that every interaction—from the first phone screening to the last follow-up visit—is handled with respect and cultural sensitivity. These interpersonal standards are being monitored with a level of rigor comparable to that required by Good Clinical Practice.


Diversity has evolved from an aspirational concept to a quantifiable performance measure. Clinical operations teams are implementing real-time tracking of demographic enrollment data, enabling timely adjustments during the recruitment period. By incorporating diversity metrics into vendor agreements and site performance expectations, the industry is embedding accountability into the recruitment process. This shift ensures that inclusive enrollment is prioritized and managed with the same discipline applied to timelines and data integrity.


The pharmaceutical sector is moving beyond the "why" of diversity and is now firmly entrenched in the "how." This holistic ecosystem does not just promise better social outcomes; it promises better science. As these strategies mature and become standardized, the result will be a clinical trial landscape that reflects the global population, leading to medicines that offer proven efficacy for every patient, regardless of their background.


More in News

APAC Laboratories Advancing Research through Cloud-Based Management Solutions

Cloud-based laboratory and research infrastructure management platforms help APAC research institutions, pharmaceutical companies and healthcare organizations manage laboratory operations. These solutions centralize research data, equipment records, sample tracking and resource management. As investments in biotechnology, pharmaceutical development and healthcare innovation increase, laboratories are adopting digital platforms to improve coordination and accessibility. Cloud technologies also support equipment monitoring, research documentation and collaboration, helping organizations strengthen data management, optimize resources and establish more efficient laboratory environments. Cloud Platforms Enhancing Laboratory Operations and Research Management Laboratories need various resources and processes to carry out experiments and move forward with research. These include equipment, chemicals and biological samples, research documentation and personnel schedules. The resources must be managed effectively and accurately, with good coordination between laboratory teams. Cloud-based laboratory management solutions are able to integrate various aspects of lab operations under a single virtual roof, making it easier for researchers and administrators to access relevant information. An important part of these systems is Laboratory Information Management Systems (LIMS). They can track the movement of samples and keep accurate records from lab to lab during research processes. These systems can be used by researchers to capture sample information, track progress of tests, and organize experimental results. A centralized sample tracking system also minimizes the risk of lost samples and erroneous records. These features are especially useful for pharmaceutical companies, diagnostic labs and biotechnology organizations with high volumes of samples in research and testing. Another critical role in which the cloud-based platform can assist is equipment management. Laboratories employ special equipment, including microscopes, centrifuges, chromatography systems and analytical testing equipment. These instruments need to be inspected, calibrated and maintained on a regular basis and have schedules and records of their work performed. Lab managers can use digital platforms to track equipment and schedule when it needs servicing, and keep records and data on the performance of their instruments. Other solutions will also notify you automatically when equipment needs maintenance or calibration. This ensures that laboratories can keep their equipment in good shape and minimize disruptions to research. Cloud-based systems also enhance how laboratory resources and staff are managed. Research laboratories may have several groups sharing the same instruments, testing rooms and other specialized equipment. Digital scheduling tools can be used by administrators to schedule equipment, make allocations of lab resources and control research activities. Laboratory schedules are available for staff to check the availability of and plan work around. This will help to maximize resources and decrease conflict between multiple research groups using the same facilities. In APAC, universities, pharmaceutical manufacturers and research institutions are keen to pursue these technologies as an effective way to modernize lab environments. Cloud-based solutions also enable smaller research organizations to have access to digital management features without building a large on-site IT infrastructure. This flexibility is helping to promote wider use throughout the region. Digital Technologies Strengthening Laboratory Data and Equipment Management Security and regulatory compliance are important factors to consider when implementing cloud solutions in labs. Research organizations can be entrusted with handling confidential experimental results, patient information, IP and sensitive commercial data. Platform providers are implementing security features for protected information, including encryption, multi-factor authentication, user access controls and monitoring of activity. These capabilities enable organizations to control access to research records and minimize the chance of unauthorized data disclosure. Laboratory management platforms are growing their capabilities with AI and data analytics. AI tools can assist researchers in managing and analyzing large datasets, detecting patterns, and interpreting experimental outcomes. Predictive analytics can help laboratory managers determine what equipment needs to be maintained, given usage history and performance data. These technologies can be used to further assist in the planning of laboratory activities and enhance the allocation of resources. The IoT is an important development that is impacting research infrastructure management. The connected sensors can keep track of the state of the laboratory, including equipment status, humidity and temperature. These measurements are especially significant for facilities that process biological material, chemicals and temperature-sensitive materials. Cloud-based platforms can gather sensor data and raise an alert if environmental conditions go beyond a set threshold. This enables the lab staff to react promptly and ensures adequate storage and operating conditions. Growing Research Investments Expanding Cloud Laboratory Solutions Across APAC Cloud-based laboratory and research infrastructure management service providers in APAC are expected to gain more opportunities with the support of scientific research and healthcare investments. With scientific research and investments in healthcare, the opportunities for cloud-based laboratory and research infrastructure management service providers in APAC are expected to increase. Rising demand in healthcare and life sciences has led to the growth of pharmaceutical companies, biotechnology firms, universities and diagnostic laboratories in terms of research capabilities. The developments are making digital systems more necessary in order to handle complicated research activities and to enable collaboration between various research facilities. Diagnostic laboratories are another significant market for these solutions. Growing testing demands are further driving a need for enhanced sample tracking, reporting and information management in the laboratory. Digital platforms enable the management of testing processes and the management of accurate records to accompany the diagnostic process by the laboratory staff. ...Read more

Regenerative Medicine on the Rise in Asia-Pacific

The Asia-Pacific (APAC) region is rapidly becoming a global leader in regenerative medicine, marked by impressive growth and innovation. Centered on repairing or replacing damaged tissues and organs, the field is poised for substantial expansion across the region’s diverse economies. While demographic shifts play a role, it is the cutting-edge scientific breakthroughs that are truly driving progress—reshaping the future of regenerative medicine and opening new possibilities for improved health outcomes. Market Landscape and Growth Drivers The APAC regenerative medicine market is experiencing robust expansion, with projections indicating a substantial increase in valuation over the coming years. The increasing prevalence of chronic and degenerative diseases, alongside an aging population across the region, creates a pressing demand for advanced therapeutic solutions that can address conditions like osteoarthritis, cardiovascular diseases, and neurological disorders. Traditional treatments often manage symptoms, whereas regenerative approaches offer fundamental repair and functional restoration potential, appealing to both patients and healthcare providers. The rising adoption of advanced medical technologies and the continuous evolution of healthcare infrastructure in many APAC countries also create a fertile environment for regenerative medicine services. As healthcare systems mature and more capable of delivering complex therapies, the accessibility and uptake of regenerative treatments are expected to climb. This includes the development of specialized centers and hospitals dedicated to regenerative medicine, further enhancing patient access. Therapeutic Modalities and Emerging Trends The regenerative medicine landscape in APAC encompasses a diverse range of therapeutic modalities. Cell-based therapies hold a significant market share, with stem cell therapies being particularly prominent. Mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and hematopoietic stem cells (HSCs) are at the forefront of research and clinical application for a wide array of conditions, including orthopedic injuries, cardiovascular disorders, and neurodegenerative diseases. Autologous (patient-derived) and allogeneic (donor-derived) cell products are increasingly developing and gaining traction. Gene therapy is another rapidly advancing segment, promising targeted treatments for genetic disorders, various cancers, and rare diseases. Breakthroughs in gene editing technologies and the development of sophisticated viral and non-viral vector delivery systems are accelerating the precision and effectiveness of these therapies. This includes advancements in CRISPR-based gene editing and innovative gene silencing techniques. Tissue engineering, which involves creating functional biological tissues to repair or replace damaged ones, is also seeing considerable innovation. This area leverages a combination of cells, biocompatible materials (biomaterials), and engineering principles. The development of advanced scaffolds, hydrogels, and 3D bioprinting technologies is revolutionizing the fabrication of complex tissues and organ structures for transplantation and regenerative purposes. Integrating artificial intelligence (AI) with bioprinting further enhances precision and functionality. Beyond these core modalities, the APAC region is witnessing a growing trend towards personalized and precision medicine in regenerative therapies. Integrating genomics, proteomics, and AI-driven analytics enables treatments to be tailored to an individual's unique genetic makeup and disease profile, promising improved efficacy and reduced side effects. This patient-centric approach fosters the development of customized stem cell treatments and patient-specific tissue engineering solutions. The application areas for regenerative medicine services are also expanding. While musculoskeletal and orthopedic disorders, particularly osteoarthritis and cartilage repair, have been traditional strongholds, there is increasing focus on dermatology (skin regeneration, scar treatment, anti-aging), cardiovascular diseases, central nervous system disorders, and oncology. The potential of regenerative therapies to provide novel solutions for previously untreatable or difficult-to-manage conditions is a major driving force. Regulatory Evolution and Regional Dynamics The regulatory landscape for regenerative medicine across APAC is diverse, with individual countries developing frameworks. This contrasts with the more harmonized approaches in regions like the US and EU. However, there is a clear trend towards establishing more robust and supportive regulatory pathways to facilitate regenerative product development, approval, and commercialization. Countries like Japan and South Korea have been particularly proactive in establishing expedited approval pathways for regenerative therapies, demonstrating a commitment to fostering innovation and patient access. Japan, for instance, has allowed for conditional marketing approval of specific regenerative therapies after demonstrating safety in Phase 1 trials, aiming to accelerate their availability. Other nations within the APAC region, including China, India, Australia, and Singapore, are also actively refining their regulatory guidelines to accommodate the unique characteristics of these advanced therapies. This includes efforts to standardize terminologies, definitions, and classifications of regenerative medicine products, providing greater clarity for developers and streamlining the approval process. The increasing number of good manufacturing practice (GMP) certified facilities for cell therapy production further underscores the region's commitment to ensuring product quality and safety. Governments are also providing significant support and funding for research institutions and biotech companies engaged in regenerative medicine, promoting a collaborative ecosystem that drives innovation. The emphasis on personalized medicine and technological innovations like advanced biomaterials and AI-powered manufacturing will likely result in more tailored and accessible treatments. Furthermore, expanding clinical trials and increasing regulatory approvals are expected to bring a broader range of regenerative products to market. As healthcare providers in the region continue to integrate regenerative approaches into mainstream medicine, the demand for specialized services and trained personnel will also grow, fostering the development of dedicated regenerative medicine departments and clinics. The APAC region is set to play an increasingly significant role in shaping the global regenerative medicine industry, driven by its research community, supportive policy environment, and ever-growing patient needs. The field's ongoing evolution promises to redefine the treatment paradigms for numerous diseases and injuries, offering renewed hope for patients across Asia. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Recent Advances and Treatment Approaches for NASH

Non-alcoholic Steatohepatitis (NASH) is a liver illness that causes inflammation and damage as a result of fat buildup, which can progress to serious problems such as cirrhosis and liver cancer. As the global frequency of NASH rises, novel therapies are being investigated through research and clinical trials. Current Therapies for NASH Lifestyle Modifications In particular, altering one's diet is essential to controlling NASH. A balanced diet low in refined carbohydrates, sweets, and saturated fats and high in fruits, vegetables, whole grains, and lean proteins can help reduce liver fat and inflammation, promote weight loss, and improve liver function. Regular exercise, at least 150 minutes a week, is crucial for managing NASH. Medications In certain NASH patients, insulin sensitizers such as pioglitazone decrease inflammation and liver fat while improving insulin sensitivity. However, there is a need for more research, and the possibility of adverse effects limits their utilization. Vitamin E antioxidants are occasionally used to treat NASH patients, but more investigation is required to ascertain the treatment's long-term safety and effectiveness. A bile acid derivative called ursodeoxycholic acid (UDCA) has been investigated for its ability to help NASH patients' livers function better and experience less inflammation. However, more research is required as its efficacy in treating NASH is yet unclear. Patients with significant obesity and NASH can benefit from bariatric surgery, such as sleeve gastrectomy or gastric bypass, which can resolve NASH and improve liver health. ...Read more
Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review . All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/the-new-era-of-representative-science-advancing-diversity-in-clinical-research-nwid-3148.html